Cognition Therapeutics (CGTX) vs ImmuCell (ICCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmuCell (ICCC) has outperformed Cognition Therapeutics (CGTX) over the past year, gaining 48.0% versus a loss of 49.1%. Over five years, ICCC leads with a +5.1% price change compared with -92.1% for CGTX. ImmuCell is the larger company by market cap ($88.6 million vs $85.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | ICCC |
|---|---|---|
| Share price | $0.8952 | $9.75 |
| Market cap | $85.13M | $88.55M |
| 1-day change | -4.42% | +0.62% |
| YTD return | -33.69% | +58.54% |
| 1-year return | -49.14% | +47.95% |
| 5-year return | -92.13% | +5.06% |
| P/E ratio (TTM) | — | 139.29 |
| EPS (TTM) | $-0.17 | $0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $12.10 |
| 52-week low | $0.55 | $4.52 |
| Distance from 52-week high | -56.33% | -19.42% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +271.98% | — |
| Average volume | 558.54K | 22.20K |
| Shares outstanding | 95.09M | 9.08M |
| Employees | 14 | 73 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed CGTX by 97.1 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Healthcare · Biotechnology · 14 employees
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Healthcare · Biotechnology · 73 employees
CGTX vs ICCC FAQ
Which is bigger, Cognition Therapeutics or ImmuCell?
ImmuCell (ICCC) is larger, with a market capitalization of $88.55M compared with $85.13M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or ICCC?
ICCC returned +47.95% over the past 12 months, compared with -49.14% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and ImmuCell in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.